Table 1.

Sensitivity (IC 50, μmol/L) of SCLC vector and WT, and SR2 vector, WT, δN, and δC cells to cisplatin, carboplatin, oxaliplatin, doxorubicin, and vinblastine

CisplatinCarboplatinOxaliplatinDoxorubicinVinblastine
SCLC
 Vector21.8 ± 0.980.3 ± 7.624.5 ± 3.50.30 ± 0.0611.1 ± 0.9
 WT12.3 ± 2.5*33.6 ± 11*15.5 ± 5.90.37 ± 0.0710.8 ± 2.0
SR2
 Vector110.6 ± 15109.7 ± 1518.8 ± 5.70.23 ± 0.049.3 ± 3.2
 WT39.7 ± 3.7§65.3 ± 12§21.1 ± 140.32 ± 0.0510.7 ± 3.3
 δN131.8 ± 11113.3 ± 5.919.4 ± 5.80.24 ± 0.069.3 ± 3.9
 δC35.2 ± 13§71.5 ± 6.6§20.4 ± 6.50.23 ± 0.0812.1 ± 1.3
  • NOTE: Data are expressed as means ± SD of triplicate measurements from three independent experiments.

  • * P < 0.01, significantly different from the results of SCLC vector (Student's t test).

  • P < 0.05, significantly different from the results of SCLC vector (Student's t test).

  • P < 0.01, significantly different from the results of SCLC vector (Student's t test).

  • § P < 0.01, significantly different from the results of SR2 vector (Student's t test).